OncoTherapy Science, Inc. (30O.F)
- Previous Close
0.0980 - Open
0.0980 - Bid 0.0910 x 190000
- Ask 0.1250 x 180000
- Day's Range
0.0980 - 0.0980 - 52 Week Range
0.0900 - 0.3080 - Volume
354 - Avg. Volume
0 - Market Cap (intraday)
23.182M - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company's pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.
www.oncotherapy.co.jpRelated News
Performance Overview: 30O.F
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 30O.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 30O.F
Valuation Measures
Market Cap
24.97M
Enterprise Value
21.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.92
Price/Book (mrq)
5.38
Enterprise Value/Revenue
0.02
Enterprise Value/EBITDA
-0.02
Financial Highlights
Profitability and Income Statement
Profit Margin
-132.30%
Return on Assets (ttm)
-61.82%
Return on Equity (ttm)
-139.74%
Revenue (ttm)
901M
Net Income Avi to Common (ttm)
-1.19B
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
598M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: 30O.F
30O.F does not have Company Insights